News
4d
Zacks Investment Research on MSNREGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?Investors will focus on profits from asthma drug Dupixent and sales of Eylea HD when biotech giant Regeneron Pharmaceuticals, ...
Dupixent hit $2.56 billion in sales in 2019 and turned in 8% growth in the first quarter to $832 million. And despite those massive growth forecasts, some analysts figure Dupixent could be on track.
The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...
Dupixent’s Growth Story Dupixent continues to be Regeneron’s primary growth driver, with global net sales reaching $3.7 billion in Q1 2025, representing 20% year-over-year growth.
Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than 300,000 adults and adolescents aged 12 years and ...
15d
Everyday Health on MSNHow Taking Two Biologics Simultaneously Is Working Out for MeConsidering dual biologic therapy for psoriasis or eczema? Get a firsthand account of navigating insurance, potential side effects, and treatment outcomes.
Dupixent is a blockbuster immunology drug that just keeps delivering for Sanofi and Regeneron, so it’s no surprise that the “franchise in a therapy” has got a new set of ads.
Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE) Late-breaking presentation at ACG 2023 showed ...
DUPIXENT may also help reduce the amount of oral corticosteroids you need while preventing severe asthma attacks and improving your breathing. DUPIXENT is not used to treat sudden breathing problems.
Dupixent beat placebo, too, but it didn’t match abrocitinib at reducing itch severity, as measured by the Peak Pruritus Numerical Rating Scale during the second week of treatment. The higher ...
The company reaffirmed its target to achieve sales of Dupixent, jointly developed with Regeneron (REGN.O), of 10 billion euros this year, up more than 20% from 8.29 billion euros in 2022.
Dupixent included in list of overseas approved drugs that meet urgent clinical need in China. Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the National Medical Products ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results